NEWS
Establishment Labs Makes a Second Donation of More Than 1,800 Reusable Face Shields
*Article originally published by Establishment Labs.
- The medical technology company focused on women’s health supported 30 organizations and institutions by donating personal protective equipment to its employees.
San José, May 12th, 2020. Establishment Labs (NASDAQ: ESTA) has continued to support health care providers in the country through the second donation of reusable face shields to 30 different organizations. The donation was made to assist workers in these institutions as they continue to deal with the COVID-19 pandemic, as well as to protect high-risk populations such as the elderly.
This initiative represents a donation of more than 1,800 reusable face shields for the staff of the selected organizations including the Ministry of Health, the Costa Rican Association of Alzheimer and Other Dementias (ASCADA), the Santiago Crespo Calvo Nursing Home, the Alfredo, and Delia González Flores Nursing Home, the Carlos María Ulloa Nursing Home, the Nursing Home of Piedades de Santa Ana, among others.
The face shields were designed in alliance with the Bionic Foundation and assembled by a team of 45 Establishment Labs employees. The face shields provide full-face coverage, are made of high-caliber transparent PSAI, and are reusable following simple cleaning and disinfecting procedures.
In April, Establishment Labs made the first donation of more than 1,000 reusable face shields to support the work of the Ministry of Health and the Manuel Antonio Chapuí andamp; Torres National Psychiatric Hospital.
About Establishment Labs
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at
www.establishmentlabs.com.
